Effectiveness and safety of sofosbuvir/ledipasvir +/- ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience

Creative Commons License

AKIN M., Buldukoglu O. Ç., ADANIR H., SÜLEYMANLAR İ., DİNÇER D., YILDIRIM B.

SAGE OPEN MEDICINE, cilt.6, 2018 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1177/2050312118781416
  • Dergi Adı: SAGE OPEN MEDICINE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Anahtar Kelimeler: Chronic hepatitis C, liver transplantation, renal transplantation, sofosbuvir/ledipasvir, ribavirin, SOFOSBUVIR PLUS RIBAVIRIN, KIDNEY-TRANSPLANT, ANTIVIRAL THERAPY, DRUG-INTERACTIONS, VIRUS-INFECTION, HCV INFECTION, GENOTYPE 1, RECIPIENTS, LEDIPASVIR, MULTICENTER
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Objective: Successful treatment is possible with novel direct-acting oral antiviral agents in solid organ transplant patients with hepatitis C. In this study, the effectiveness and safety of sofosbuvir/ledipasvir +/- ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C were evaluated.